Schering "buy"

12/09/05 - Merck Finck & Co.

LONDON, December 9 (newratings.com) – Analyst Carsten Kunold of Merck Finck & Co reiterates his "buy" rating on Schering AG (SH-EUR).

In a research note published this morning, the analyst mentions that the FDA has extended the review period for the company’s YAZ. The analyst expects the FDA’s decision to be announced in 1Q06, given the extension. The FDA has also asked Schering to invest €1 billion for the exclusive marketing rights of Betaseron, following patent expiry due in 2008 on account of the take-over of Chiron by Novartis, Merck Finck & Co says.